End Stage Renal Disease (ESRD) Drug Market Report 2026

The end stage renal disease (esrd) drug market size has grown rapidly in recent years. It will grow from $148.55 billion in 2025 to $171.12 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to growing prevalence of ckd, increasing awareness of esrd, rise in dialysis centers, advancements in renal therapeutics, government healthcare initiatives.

The end stage renal disease (esrd) drug market size is expected to see rapid growth in the next few years. It will grow to $304.07 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to development of precision medicine, expansion of homecare dialysis, integration of ai in patient monitoring, rising investments in esrd r&d, growing adoption of combination therapies. Major trends in the forecast period include personalized esrd drug therapy, home-based dialysis solutions, telemedicine integration in ckd management, advanced drug formulations for secondary complications, increasing adoption of combination therapies.

The increasing prevalence of obesity and diabetes is expected to drive the growth of the end-stage renal disease (ESRD) drug market in the coming years. Obesity is defined as excessive or abnormal fat accumulation that presents a health risk, while diabetes is a long-term condition that occurs when the pancreas produces insufficient insulin or when the body cannot effectively use the insulin it produces. In individuals with renal disease, effective management of fluid and electrolyte balance, blood pressure, and waste removal through dialysis can enhance overall health and well-being, potentially contributing to weight loss and better blood glucose control. For example, in 2023, the World Obesity Federation, a non-profit membership organization, projected that by 2035 the economic burden of overweight and obesity would reach US$4.32 trillion annually, representing nearly 3% of the global economy. Additionally, in June 2024, according to the National Health Service, a UK-based government body, 3,615,330 people registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, reflecting an 18% increase from 3,065,825 cases in 2022. Therefore, the rising incidence of obesity and diabetes is fueling the growth of the end-stage renal disease (ESRD) drug market.

Major companies operating in the end-stage renal disease (ESRD) drug market are emphasizing product approvals, such as Jardiance, to boost their market revenues. Empagliflozin is a medication designed to support individuals with type 2 diabetes and to reduce the risk of cardiovascular complications in patients with type 2 diabetes who also have heart failure or cardiovascular disease. For example, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, received FDA approval for Jardiance. Jardiance has been approved for multiple indications, including reducing the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression, as well as decreasing the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults with heart failure. Jardiance is classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor and is contraindicated for patients with type 1 diabetes and those with an eGFR below 20 ml/min/1.73 m².

In May 2024, Vertex Pharmaceuticals, a U.S.-based biotechnology company focused on developing therapies for genetic disorders and immunology, acquired Alpine Immune Sciences for an undisclosed sum. Through this acquisition, Vertex sought to broaden its renal disease portfolio by obtaining povetacicept, Alpine’s lead candidate targeting IgA nephropathy (IgAN), a chronic autoimmune kidney condition that can progress to end-stage renal disease, while also integrating Alpine’s protein engineering and immunotherapy expertise. Alpine Immune Sciences is a U.S.-based clinical-stage biotechnology company specializing in engineered immunotherapies, with its dual BAFF/APRIL antagonist povetacicept expected to advance into Phase 3 development for IgAN.

Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA.

North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the end stage renal disease (esrd) drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the ESRD drug market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials, leading to higher production costs and supply chain disruptions. The impact is most pronounced in segments like vitamin D analogs and calcimimetics, especially in regions reliant on imports such as Asia-Pacific and Africa. Hospitals and specialty clinics face increased procurement costs, whereas domestic manufacturers may benefit from reduced competition, prompting investment in local production and innovation to optimize cost-effective therapies.

The end stage renal disease (esrd) drug market research report is one of a series of new reports that provides end stage renal disease (esrd) drug market statistics, including end stage renal disease (esrd) drug industry global market size, regional shares, competitors with a end stage renal disease (esrd) drug market share, detailed end stage renal disease (esrd) drug market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (esrd) drug industry. This end stage renal disease (esrd) drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

End stage renal disease (ESRD) drugs are medications used to manage a condition in which a person’s kidneys permanently lose function, necessitating a kidney transplant or ongoing long-term dialysis to sustain life. These drugs play a vital role in treating the disease and preventing secondary complications in patients with chronic kidney disease (CKD).

The primary types of end stage renal disease (ESRD) drugs include calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics are used to lower parathyroid hormone (PTH) levels in patients with stage 5D kidney disease, based on serum calcium and phosphorus concentrations. Key indications include ESRD-induced hyperparathyroidism, ESRD-induced hyperphosphatemia, and ESRD-induced hyperkalemia. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and are used across hospitals, homecare settings, specialty clinics, and other end users.

The end-stage renal disease (ESRD) drug market consists of sales of cinacalcet hcl, diuretics, sevelamer, epoetin alfa, and over-the-counter drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.